Anavex Life Sciences Corp. (NASDAQ:AVXL) shares traded down 4.5% during mid-day trading on Tuesday . The stock traded as low as $6.90 and last traded at $7.04, with a volume of 806,566 shares. The stock had previously closed at $7.37.

Several research analysts have recently issued reports on the stock. Zacks Investment Research downgraded shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Tuesday, July 12th. Maxim Group reiterated a “buy” rating and issued a $15.00 target price on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd. Finally, FBR & Co reiterated a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Wednesday, June 22nd.

The firm’s 50-day moving average is $5.28 and its 200-day moving average is $4.81. The company’s market capitalization is $249.97 million.

Anavex Life Sciences Corp. (NASDAQ:AVXL) last posted its quarterly earnings results on Wednesday, May 11th. The company reported ($0.06) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.16) by $0.10. Equities analysts anticipate that Anavex Life Sciences Corp. will post ($0.34) EPS for the current fiscal year.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.